Chapters

Transcript

Video

What results from LEADER, showing CV risk reduction with liraglutide, do you think are most important and how are they likely to change our use of GLP-1 RAs in high risk patients with T2D?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Robert Henry, MD

Robert Henry, MD

Chief, Center for Metabolic Research
Chief, Section of Endocrinology, Metabolism & Diabetes
Veterans Affairs Healthcare System
Professor of Medicine‚ Department of Medicine
Division of Endocrinology and Metabolism
University of California‚ San Diego